Passer au contenu principal

Votre navigateur n’est malheureusement pas entièrement pris en charge. Si vous avez la possibilité de le faire, veuillez passer à une version plus récente ou utiliser Mozilla Firefox, Microsoft Edge, Google Chrome, ou Safari 14 ou plus récent. Si vous n’y parvenez pas et que vous avez besoin d’aide, veuillez nous faire part de vos commentaires.

Nous vous serions reconnaissants de nous faire part de vos commentaires sur cette nouvelle expérience.Faites-nous part de votre opinion

Elsevier
Publier avec nous

Bienvenue sur Elsevier Connect

Actualités, informations et dossiers pour les communautés de la recherche, de la santé et de la technologie.

Students sitting around a table at library

À l’honneur

The future we build could depend on research we don’t read

Policy is meant to be shaped by evidence. But what happens when the most relevant research never reaches decision-makers?

New research supported by Elsevier datasets suggests that roughly two-thirds of highly policy-relevant science may go uncited — not because it lacks quality, but because it remains invisible. As AI becomes part of how evidence is found and synthesized, trusted sources, transparency and broader visibility are becoming essential to better decisions.

What if the next life-saving drug is buried in a patent diagram?

In drug discovery, the evidence researchers need often already exists — scattered across journals, patents, figures and chemical diagrams that conventional search may miss.

AI-supported workflows grounded in trusted scientific knowledge are helping researchers connect chemistry, bioactivity and patent evidence faster, with insights traceable back to their sources. From surfacing hidden chemistry in images to exploring millions of drug–disease connections at scale, better access to quality information can help teams move from search to decision with greater confidence.